Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

NCT#: & Link

NCT05512377

NCT QR Code

Available as of:

July 15 2024

Contract:

Caris

Indication Category:

Solid Tumors

Study Sponsor:

Boehringer
Ingelheim

Protocol #:

1403-0011

Title:

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

Highlight Details:

Brightline 2- A Phase II/III, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/metastatic, MDM2 amplified, TP53 wild-type solid tumours-biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumors

Biomarkers:

MDM2 amplification

Indication:

Select solid tumors

Phase:

2

Treatment Line:

Study Drug/Test Compound:

BI 907828

Notes

Recruitment Status:

Just In Time

Participating Institution:

Salinas Valley Health

Salinas Valley Health Clinical Research Program:

Terri Nielsen, MSJ, RN, CCRP, Clinical Research Program Manager, research@salinasvalleyhealth.com